Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedAdded related topic links for Melanoma and MedlinePlus Genetics on the Study Details page.SummaryDifference0.2%

- Check11 days agoChange DetectedThe page now shows Revision: v3.4.2 and removed Revision: v3.4.1 along with the topics Melanoma and related topics: MedlinePlus Genetics; these are metadata updates and do not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedThe page adds a melanoma topic tag, related topics: MedlinePlus Genetics, and revision v3.4.1 (replacing v3.4.0); these metadata updates do not alter the study content, eligibility criteria, or reported outcomes, and to avoid alerts for small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check19 days agoChange DetectedThe page adds a Melanoma label and MedlinePlus Genetics related topics, and updates the revision badge to v3.4.1 (removing v3.4.0).SummaryDifference0.2%

- Check27 days agoChange DetectedThe changes are minor UI and metadata updates: a Show glossary option was added, QC-related labels such as Last Update Submitted that Met QC Criteria and release notes (Revision: v3.4.0; No FEAR Act Data) were introduced, while some related topics and older revision notes (e.g., MedlinePlus Genetics, Revision: v3.3.4) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedMelanoma is now listed as a related topic and a MedlinePlus Genetics link has been added under related topics.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.